49 results on '"Kristensen, Søren L."'
Search Results
2. Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus
3. Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis
4. Burden and Causes of Hospital Admissions in Heart Failure During the Last Year of Life
5. Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study
6. Trends in Medical and Device Therapies Following Incident Heart Failure in Denmark during 1996–2019: A Nationwide Register-Based Follow-Up Study
7. Low-Dose Aspirin in Heart Failure Not Complicated by Atrial Fibrillation: A Nationwide Propensity-Matched Study
8. Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure
9. SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease
10. Ventricular rate in atrial fibrillation and the risk of heart failure and death
11. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status
12. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro–B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
13. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure
14. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial
15. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
16. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)
17. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction
18. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation
19. Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer
20. Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
21. Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis
22. Risk of heart failure in type 2 diabetes complicated by incident ischaemic heart disease and end‐stage renal disease
23. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF
24. Employment status at time of first hospitalization for heart failure is associated with death and rehospitalization for heart failure
25. Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure: a nationwide cohort study
26. Evidence based therapy and its association with workforce detachment following first hospitalization for heart failure
27. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure
28. HIGH FIVE-YEAR SURVIVAL IN HEART FAILURE PATIENTS YOUNGER THAN 70 YEARS WITHOUT SEVERE COMORBIDITIES
29. Individualizing surgical revascularization in patients with ischaemic heart failure — a further dive into STICHES
30. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes
31. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction. A report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve)
32. Return to the workforce following first hospitalization for heart failure: a Danish nationwide cohort study
33. Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
34. Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction
35. Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure
36. Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial
37. Syncope and Its Impact on Occupational Accidents and Employment
38. Return to the Workforce After First Hospitalization for Heart Failure
39. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
40. Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial.
41. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease:A nationwide cohort study
42. Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction
43. International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction
44. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction
45. Antithrombotic Treatment in Patients With Heart Failure and Associated Atrial Fibrillation and Vascular Disease
46. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction.
47. Anthropometric measures and long‐term mortality in non‐ischaemic heart failure with reduced ejection fraction: Questioning the obesity paradox.
48. The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.
49. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.